Semaglutide vs Tirzepatide: what is the difference
The difference is how many receptors each one hits. Semaglutide is an analog of human GLP-1 with 94% homology and a half-life near seven days, which is what makes once-weekly dosing possible. Tirzepatide activates two incretin receptors at once, GIP and GLP-1. Both are approved for type 2 diabetes and for chronic weight management.
Key parameters side by side
Parameter
Semaglutide
Tirzepatide
Sequence length
31
39
Molecular weight
4113.58 Da
4813.45 Da
Same for both: Category — Weight Loss; Evidence status — Approved
Frequently asked questions
Semaglutide activates a single receptor, GLP-1, reproducing the native hormone with structural changes that extend its life. Tirzepatide is a first-in-class dual agonist: it switches on the GIP and GLP-1 receptors together, two complementary metabolic axes.
Both completed the full regulatory path. Semaglutide is approved under three brand names and cleared by more than a hundred national regulators; tirzepatide holds three FDA approvals under two brand names — type 2 diabetes since 2022, weight management since 2023.
Weight Loss
Semaglutide
Approved
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk for the treatment of type 2 diabetes and later approved for chronic weight management. It is a modified analog of human GLP-1(7-37) with 94% amino acid homology to the native hormone, engineered with key structural modifications that extend its half-life to approximately 7 days — enabling once-weekly dosing.
The molecule features three critical modifications: an Aib (alpha-aminoisobutyric acid) substitution at position 8 conferring DPP-4 resistance, a C18 fatty diacid chain attached to lysine at position 26 enabling strong albumin binding, and a small amino acid substitution at position 34. These modifications solved the fundamental pharmacokinetic limitation of native GLP-1, which has a half-life of only 2-3 minutes.
Semaglutide represents one of the most commercially successful peptide therapeutics in pharmaceutical history, with demonstrated efficacy in reducing HbA1c by 1.5-1.8% and producing weight loss of 15-17% of body weight in clinical trials — substantially exceeding all prior anti-obesity medications.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023), it represents a paradigm shift in incretin-based therapy by simultaneously activating two complementary metabolic hormone receptors.
The 39-amino acid peptide is based on the native GIP sequence with modifications enabling GLP-1R co-agonism, DPP-4 resistance (Aib at positions 2 and 13), and albumin binding via a C20 fatty diacid chain. This dual mechanism produces unprecedented metabolic outcomes: up to 2.4% HbA1c reduction and 22.5% body weight loss in clinical trials — substantially exceeding single-agonist therapies.
Tirzepatide's unique mechanism of simultaneously enhancing GIP and GLP-1 signaling addresses both central appetite regulation and peripheral metabolic control, positioning it as a potential cornerstone of next-generation obesity and diabetes pharmacotherapy.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk for the treatment of type 2 diabetes and later approved for chronic weight management. It is a modified analog of human GLP-1(7-37) with 94% amino acid homology to the native hormone, engineered with key structural modifications that extend its half-life to approximately 7 days — enabling once-weekly dosing.
The molecule features three critical modifications: an Aib (alpha-aminoisobutyric acid) substitution at position 8 conferring DPP-4 resistance, a C18 fatty diacid chain attached to lysine at position 26 enabling strong albumin binding, and a small amino acid substitution at position 34. These modifications solved the fundamental pharmacokinetic limitation of native GLP-1, which has a half-life of only 2-3 minutes.
Semaglutide represents one of the most commercially successful peptide therapeutics in pharmaceutical history, with demonstrated efficacy in reducing HbA1c by 1.5-1.8% and producing weight loss of 15-17% of body weight in clinical trials — substantially exceeding all prior anti-obesity medications.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023), it represents a paradigm shift in incretin-based therapy by simultaneously activating two complementary metabolic hormone receptors.
The 39-amino acid peptide is based on the native GIP sequence with modifications enabling GLP-1R co-agonism, DPP-4 resistance (Aib at positions 2 and 13), and albumin binding via a C20 fatty diacid chain. This dual mechanism produces unprecedented metabolic outcomes: up to 2.4% HbA1c reduction and 22.5% body weight loss in clinical trials — substantially exceeding single-agonist therapies.
Tirzepatide's unique mechanism of simultaneously enhancing GIP and GLP-1 signaling addresses both central appetite regulation and peripheral metabolic control, positioning it as a potential cornerstone of next-generation obesity and diabetes pharmacotherapy.